6642-36-0

Usage

Uses

Used in Pharmaceutical Industry:
1-(2-chlorophenyl)-2,2-dimethyl-propan-1-ol is used as a sedative and hypnotic medication for the treatment of various conditions. Its application is primarily due to its ability to induce a calming effect and promote sleep, which is beneficial for patients experiencing insomnia or anxiety.
Used in Treatment of Alcohol Withdrawal Syndrome:
In the medical field, 1-(2-chlorophenyl)-2,2-dimethyl-propan-1-ol is also utilized as a treatment for alcohol withdrawal syndrome. Its sedative and hypnotic effects help alleviate the symptoms associated with alcohol withdrawal, providing relief and support during the recovery process.
Used in Research Settings:
Chlormethiazole is employed in research as a tool to study its effects on the nervous system. Its anticonvulsant and anaesthetic properties make it a valuable compound for investigating potential treatments for various neurological conditions. 1-(2-chlorophenyl)-2,2-dimethyl-propan-1-ol's interaction with the nervous system offers insights into its potential therapeutic applications.

InChI:InChI=1/C11H15ClO/c1-11(2,3)10(13)8-6-4-5-7-9(8)12/h4-7,10,13H,1-3H3

Upstream product

• 677-22-5 tert-butylmagnesium chloride 
• 15842-76-9 (2-chloro-phenyl)-trimethyl-silane 
• 630-19-3 pivalaldehyde 

Relevant academic research and scientific papers

Base-modified thymidines capable of terminating DNA synthesis are novel bioactive compounds with activity in cancer cells

Current FDA-approved chemotherapeutic antimetabolites elicit severe side effects that warrant their improvement; therefore, we designed compounds with mechanisms of action focusing on inhibiting DNA replication rather than targeting multiple pathways. We previously discovered that 5-(α-substituted-2-nitrobenzyloxy)methyluridine-5′-triphosphates were exquisite DNA synthesis terminators; therefore, we synthesized a library of 35 thymidine analogs and evaluated their activity using an MTT cell viability assay of MCF7 breast cancer cells chosen for their vulnerability to these nucleoside derivatives. Compound 3a, having an α-tert-butyl-2-nitro-4-(phenyl)alkynylbenzyloxy group, showed an IC50 of 9 ± 1 μM. The compound is more selective for cancer cells than for fibroblast cells compared with 5-fluorouracil. Treatment of MCF7 cells with 3a elicits the DNA damage response as indicated by phosphorylation of γ-H2A. A primer extension assay of the 5′-triphosphate of 3a revealed that 3aTP is more likely to inhibit DNA polymerase than to lead to termination events upon incorporation into the DNA replication fork.

Bu4N+ alkoxide-initiated/autocatalytic addition reactions with organotrimethylsilanes

The use of Me3SiO-/Bu4N+ as a general activator of organotrimethylsilanes for addition reactions has been established. The broad scope of the method offers trimethylsilanes (including acetate, allyl, propargyl, benzyl, dithiane, heteroaryl, and aryl derivatives) as bench-stable organometallics that can be readily utilized as carbanion equivalents for synthesis. Reactions are achieved at rt without the requirement of specialized precautions that are commonplace for other organometallics.

NOVEL NANOCARRIER DELIVERED CANCER CHEMOTHERAPEUTIC AGENTS

Compositions and methods for treating cancer in a subject are described herein. The composition includes modified nucleobases and nucleosides that are converted in the cell to nucleotides that are incorporated into growing DNA and result in termination of